TD Cowen analyst Marc Frahm has maintained their bullish stance on BPMC stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Marc Frahm has given his Buy rating due to a combination of factors that highlight Blueprint Medicines’ strong market position and growth potential. The company reported robust Q4 Ayvakit revenues of $144.1 million, slightly exceeding market expectations and demonstrating a significant year-over-year increase. This growth was driven by stable patient additions, high compliance, and low percentages of free drug distribution, a positive indication of market demand and product adoption.
Furthermore, Blueprint Medicines has issued a conservative fiscal year 2025 guidance of $680-710 million, which considers ongoing U.S. demand growth and anticipated increases in reimbursement outside the U.S. The company’s management has also observed a broadening in the prescribing base, notably among allergists, dermatologists, and gastroenterologists, which suggests expanding market penetration. The initiation of BLU-808 POC trials and expectations for data reporting by the end of 2025 further support the Buy recommendation, indicating potential for future product developments and revenue growth.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $130.00 price target.